De Novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer

Saber Tadros, Surendra K. Shukla, Ryan J. King, Venugopal Gunda, Enza Vernucci, Jaime Abrego, Nina V. Chaika, Fang Yu, Audrey J Lazenby, Lyudmyla Berim, Jean L Grem, Aaron R. Sasson, Pankaj Singh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is moderately responsive to gemcitabine-based chemotherapy, the most widely used single-agent therapy for pancreatic cancer. Although the prognosis in pancreatic cancer remains grim in part due to poor response to therapy, previous attempts at identifying and targeting the resistance mechanisms have not been very successful. By leveraging The Cancer Genome Atlas dataset, we identified lipid metabolism as the metabolic pathway that most significantly correlated with poor gemcitabine response in pancreatic cancer patients. Furthermore, we investigated the relationship between alterations in lipogenesis pathway and gemcitabine resistance by utilizing tissues from the genetically engineered mouse model and human pancreatic cancer patients. We observed a significant increase in fatty acid synthase (FASN) expression with increasing disease progression in spontaneous pancreatic cancer mouse model, and a correlation of high FASN expression with poor survival in patients and poor gemcitabine responsiveness in cell lines. We observed a synergistic effect of FASN inhibitors with gemcitabine in pancreatic cancer cells in culture and orthotopic implantation models. Combination of gemcitabine and the FASN inhibitor orlistat significantly diminished stemness, in part due to induction of endoplasmic reticulum (ER) stress that resulted in apoptosis. Moreover, direct induction of ER stress with thapsigargin caused a similar decrease in stemness and showed synergistic activity with gemcitabine. Our in vivo studies with orthotopic implantation models demonstrated a robust increase in gemcitabine responsiveness upon inhibition of fatty acid biosynthesis with orlistat. Altogether, we demonstrate that fatty acid biosynthesis pathway manipulation can help overcome the gemcitabine resistance in pancreatic cancer by regulating ER stress and stemness.

Original languageEnglish (US)
Pages (from-to)5503-5517
Number of pages15
JournalCancer Research
Volume77
Issue number20
DOIs
StatePublished - Oct 15 2017

Fingerprint

gemcitabine
Endoplasmic Reticulum Stress
Pancreatic Neoplasms
Lipids
Fatty Acid Synthases
Fatty Acids
Lipogenesis
Thapsigargin
Atlases
Metabolic Networks and Pathways
Lipid Metabolism

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

De Novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer. / Tadros, Saber; Shukla, Surendra K.; King, Ryan J.; Gunda, Venugopal; Vernucci, Enza; Abrego, Jaime; Chaika, Nina V.; Yu, Fang; Lazenby, Audrey J; Berim, Lyudmyla; Grem, Jean L; Sasson, Aaron R.; Singh, Pankaj.

In: Cancer Research, Vol. 77, No. 20, 15.10.2017, p. 5503-5517.

Research output: Contribution to journalArticle

Tadros, Saber ; Shukla, Surendra K. ; King, Ryan J. ; Gunda, Venugopal ; Vernucci, Enza ; Abrego, Jaime ; Chaika, Nina V. ; Yu, Fang ; Lazenby, Audrey J ; Berim, Lyudmyla ; Grem, Jean L ; Sasson, Aaron R. ; Singh, Pankaj. / De Novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer. In: Cancer Research. 2017 ; Vol. 77, No. 20. pp. 5503-5517.
@article{19890f4147c142e5b73bac5fffea68f2,
title = "De Novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer",
abstract = "Pancreatic adenocarcinoma is moderately responsive to gemcitabine-based chemotherapy, the most widely used single-agent therapy for pancreatic cancer. Although the prognosis in pancreatic cancer remains grim in part due to poor response to therapy, previous attempts at identifying and targeting the resistance mechanisms have not been very successful. By leveraging The Cancer Genome Atlas dataset, we identified lipid metabolism as the metabolic pathway that most significantly correlated with poor gemcitabine response in pancreatic cancer patients. Furthermore, we investigated the relationship between alterations in lipogenesis pathway and gemcitabine resistance by utilizing tissues from the genetically engineered mouse model and human pancreatic cancer patients. We observed a significant increase in fatty acid synthase (FASN) expression with increasing disease progression in spontaneous pancreatic cancer mouse model, and a correlation of high FASN expression with poor survival in patients and poor gemcitabine responsiveness in cell lines. We observed a synergistic effect of FASN inhibitors with gemcitabine in pancreatic cancer cells in culture and orthotopic implantation models. Combination of gemcitabine and the FASN inhibitor orlistat significantly diminished stemness, in part due to induction of endoplasmic reticulum (ER) stress that resulted in apoptosis. Moreover, direct induction of ER stress with thapsigargin caused a similar decrease in stemness and showed synergistic activity with gemcitabine. Our in vivo studies with orthotopic implantation models demonstrated a robust increase in gemcitabine responsiveness upon inhibition of fatty acid biosynthesis with orlistat. Altogether, we demonstrate that fatty acid biosynthesis pathway manipulation can help overcome the gemcitabine resistance in pancreatic cancer by regulating ER stress and stemness.",
author = "Saber Tadros and Shukla, {Surendra K.} and King, {Ryan J.} and Venugopal Gunda and Enza Vernucci and Jaime Abrego and Chaika, {Nina V.} and Fang Yu and Lazenby, {Audrey J} and Lyudmyla Berim and Grem, {Jean L} and Sasson, {Aaron R.} and Pankaj Singh",
year = "2017",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-16-3062",
language = "English (US)",
volume = "77",
pages = "5503--5517",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - De Novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer

AU - Tadros, Saber

AU - Shukla, Surendra K.

AU - King, Ryan J.

AU - Gunda, Venugopal

AU - Vernucci, Enza

AU - Abrego, Jaime

AU - Chaika, Nina V.

AU - Yu, Fang

AU - Lazenby, Audrey J

AU - Berim, Lyudmyla

AU - Grem, Jean L

AU - Sasson, Aaron R.

AU - Singh, Pankaj

PY - 2017/10/15

Y1 - 2017/10/15

N2 - Pancreatic adenocarcinoma is moderately responsive to gemcitabine-based chemotherapy, the most widely used single-agent therapy for pancreatic cancer. Although the prognosis in pancreatic cancer remains grim in part due to poor response to therapy, previous attempts at identifying and targeting the resistance mechanisms have not been very successful. By leveraging The Cancer Genome Atlas dataset, we identified lipid metabolism as the metabolic pathway that most significantly correlated with poor gemcitabine response in pancreatic cancer patients. Furthermore, we investigated the relationship between alterations in lipogenesis pathway and gemcitabine resistance by utilizing tissues from the genetically engineered mouse model and human pancreatic cancer patients. We observed a significant increase in fatty acid synthase (FASN) expression with increasing disease progression in spontaneous pancreatic cancer mouse model, and a correlation of high FASN expression with poor survival in patients and poor gemcitabine responsiveness in cell lines. We observed a synergistic effect of FASN inhibitors with gemcitabine in pancreatic cancer cells in culture and orthotopic implantation models. Combination of gemcitabine and the FASN inhibitor orlistat significantly diminished stemness, in part due to induction of endoplasmic reticulum (ER) stress that resulted in apoptosis. Moreover, direct induction of ER stress with thapsigargin caused a similar decrease in stemness and showed synergistic activity with gemcitabine. Our in vivo studies with orthotopic implantation models demonstrated a robust increase in gemcitabine responsiveness upon inhibition of fatty acid biosynthesis with orlistat. Altogether, we demonstrate that fatty acid biosynthesis pathway manipulation can help overcome the gemcitabine resistance in pancreatic cancer by regulating ER stress and stemness.

AB - Pancreatic adenocarcinoma is moderately responsive to gemcitabine-based chemotherapy, the most widely used single-agent therapy for pancreatic cancer. Although the prognosis in pancreatic cancer remains grim in part due to poor response to therapy, previous attempts at identifying and targeting the resistance mechanisms have not been very successful. By leveraging The Cancer Genome Atlas dataset, we identified lipid metabolism as the metabolic pathway that most significantly correlated with poor gemcitabine response in pancreatic cancer patients. Furthermore, we investigated the relationship between alterations in lipogenesis pathway and gemcitabine resistance by utilizing tissues from the genetically engineered mouse model and human pancreatic cancer patients. We observed a significant increase in fatty acid synthase (FASN) expression with increasing disease progression in spontaneous pancreatic cancer mouse model, and a correlation of high FASN expression with poor survival in patients and poor gemcitabine responsiveness in cell lines. We observed a synergistic effect of FASN inhibitors with gemcitabine in pancreatic cancer cells in culture and orthotopic implantation models. Combination of gemcitabine and the FASN inhibitor orlistat significantly diminished stemness, in part due to induction of endoplasmic reticulum (ER) stress that resulted in apoptosis. Moreover, direct induction of ER stress with thapsigargin caused a similar decrease in stemness and showed synergistic activity with gemcitabine. Our in vivo studies with orthotopic implantation models demonstrated a robust increase in gemcitabine responsiveness upon inhibition of fatty acid biosynthesis with orlistat. Altogether, we demonstrate that fatty acid biosynthesis pathway manipulation can help overcome the gemcitabine resistance in pancreatic cancer by regulating ER stress and stemness.

UR - http://www.scopus.com/inward/record.url?scp=85031426423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031426423&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-3062

DO - 10.1158/0008-5472.CAN-16-3062

M3 - Article

VL - 77

SP - 5503

EP - 5517

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -